ORBIMED CAPITAL LLC — SEC Form 4 filings
SEC reporting owner CIK 1157524. 4 Form 4 filings on record with FilingPulse; latest filed 2026-04-23.
Transaction summary — filings shown
Covers all 4 filings on record, filed 2024-04-05 to 2026-04-23. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 1 filing — 2,815,315 shares, $12,499,999 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 5 legs across 2 filings — 952,377 shares, $12,585,998 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 5.
- Largest priced transaction: purchase of 1,689,189 shares @ $4.44 ($7,499,999) in Prelude Therapeutics Inc, filed 2026-04-23.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | Director | 2 | — | 5 legs · 952,377 sh · $12,585,998 | — |
| Prelude Therapeutics Inc (PRLD) | Director, 10% owner | 1 | 2 legs · 2,815,315 sh · $12,499,999 | — | — |
| Kinnate Biopharma Inc. (KNTE) | Director, 10% owner | 1 | — | — | 5 |
Form 4 filings — ORBIMED CAPITAL LLC
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-04-23 | 4 | Prelude Therapeutics Inc (PRLD) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VI LLC, OrbiMed Genesis GP LLC | Purchase (P): 1,689,189 @ $4.44 · Purchase (P): 1,126,126 @ $4.44 | EDGAR |
| 2024-08-28 | 4 | ARS Pharmaceuticals, Inc. (SPRY) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VI LLC | Sale (S): 83,695 @ $13 | EDGAR |
| 2024-08-23 | 4 | ARS Pharmaceuticals, Inc. (SPRY) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VI LLC | Sale (S): 394,400 @ $13.52 · Sale (S): 13,300 @ $14.61 · Sale (S): 391,482 @ $12.94 · Sale (S): 69,500 @ $13.03 | EDGAR |
| 2024-04-05 | 4 | Kinnate Biopharma Inc. (KNTE) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VII LLC, OrbiMed Capital GP VIII LLC, OrbiMed Asia GP IV, L.P., OrbiMed Advisors IV Ltd, OrbiMed Genesis GP LLC | Disposition to issuer (D): 1,368,339 · Disposition to issuer (D): 4,738,453 · Disposition to issuer (D): 1,368,338 · Disposition to issuer (D): 84,599 · Disposition to issuer (D): 450,000 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1157524 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →